Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
919 | 11160 | 47.3 | 93% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
10 | 3 | IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL | 134299 |
919 | 2 | PD L1//PD 1//FOXP3 | 11160 |
110 | 1 | FOXP3//REGULATORY T CELLS//TREG | 4345 |
721 | 1 | PD L1//PD 1//IPILIMUMAB | 3134 |
2395 | 1 | CD28//COSTIMULATION//B7 | 2259 |
16595 | 1 | TIM 3//GALECTIN 9//TIM 1 | 646 |
23216 | 1 | B7 H4//B7 H3//SOLUBLE B7 H4 | 354 |
24008 | 1 | ICOS//B7RP 1//INDUCIBLE COSTIMULATOR | 326 |
35492 | 1 | LAG 3//LYMPHOCYTE ACTIVATION GENE 3//CD223 | 96 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PD L1 | authKW | 762668 | 3% | 73% | 382 |
2 | PD 1 | authKW | 710500 | 4% | 62% | 422 |
3 | FOXP3 | authKW | 677638 | 6% | 39% | 634 |
4 | REGULATORY T CELLS | authKW | 655190 | 9% | 23% | 1052 |
5 | IPILIMUMAB | authKW | 459281 | 2% | 61% | 275 |
6 | NIVOLUMAB | authKW | 377275 | 2% | 76% | 182 |
7 | COSTIMULATION | authKW | 327149 | 4% | 29% | 413 |
8 | CTLA 4 | authKW | 318115 | 3% | 35% | 336 |
9 | TIM 3 | authKW | 291388 | 1% | 81% | 131 |
10 | PEMBROLIZUMAB | authKW | 250413 | 1% | 78% | 118 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Immunology | 150768 | 55% | 1% | 6170 |
2 | Oncology | 10086 | 17% | 0% | 1919 |
3 | Transplantation | 8805 | 6% | 1% | 691 |
4 | Medicine, Research & Experimental | 5301 | 9% | 0% | 1024 |
5 | Hematology | 1837 | 5% | 0% | 526 |
6 | Cell Biology | 1316 | 8% | 0% | 849 |
7 | Allergy | 1290 | 2% | 0% | 200 |
8 | Rheumatology | 1053 | 2% | 0% | 231 |
9 | Surgery | 307 | 5% | 0% | 582 |
10 | Pathology | 189 | 2% | 0% | 212 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | IMMUNOL | 82701 | 14% | 2% | 1563 |
2 | LUDWIG CANC IMMUNOTHER Y | 82067 | 1% | 52% | 58 |
3 | IMMUNOL IMMUNOPATHOL | 65356 | 1% | 36% | 66 |
4 | CELL SIGNALLING SECT | 25911 | 0% | 59% | 16 |
5 | UNIT IMMUNE HOMEOSTASIS | 25510 | 0% | 67% | 14 |
6 | NEUROL DIS | 24788 | 1% | 7% | 122 |
7 | TRANSPLANTAT IMMUNOL GRP | 22853 | 0% | 25% | 34 |
8 | IMMUNE TOLERANCE | 21199 | 0% | 52% | 15 |
9 | MED ONCOL IMMUNOTHER Y | 20689 | 0% | 32% | 24 |
10 | DONALD A ADAM COMPREHENS MELANOMA | 15744 | 0% | 52% | 11 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF IMMUNOLOGY | 82214 | 11% | 2% | 1274 |
2 | CANCER IMMUNOLOGY RESEARCH | 51395 | 1% | 20% | 92 |
3 | EUROPEAN JOURNAL OF IMMUNOLOGY | 31822 | 4% | 3% | 394 |
4 | IMMUNITY | 20686 | 1% | 5% | 162 |
5 | ONCOIMMUNOLOGY | 19572 | 1% | 9% | 83 |
6 | JOURNAL OF EXPERIMENTAL MEDICINE | 17340 | 3% | 2% | 282 |
7 | INTERNATIONAL IMMUNOLOGY | 14287 | 1% | 4% | 146 |
8 | NATURE IMMUNOLOGY | 11498 | 1% | 4% | 97 |
9 | CLINICAL IMMUNOLOGY | 9862 | 1% | 4% | 99 |
10 | IMMUNOTHERAPY | 9783 | 0% | 7% | 51 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PD L1 | 762668 | 3% | 73% | 382 | Search PD+L1 | Search PD+L1 |
2 | PD 1 | 710500 | 4% | 62% | 422 | Search PD+1 | Search PD+1 |
3 | FOXP3 | 677638 | 6% | 39% | 634 | Search FOXP3 | Search FOXP3 |
4 | REGULATORY T CELLS | 655190 | 9% | 23% | 1052 | Search REGULATORY+T+CELLS | Search REGULATORY+T+CELLS |
5 | IPILIMUMAB | 459281 | 2% | 61% | 275 | Search IPILIMUMAB | Search IPILIMUMAB |
6 | NIVOLUMAB | 377275 | 2% | 76% | 182 | Search NIVOLUMAB | Search NIVOLUMAB |
7 | COSTIMULATION | 327149 | 4% | 29% | 413 | Search COSTIMULATION | Search COSTIMULATION |
8 | CTLA 4 | 318115 | 3% | 35% | 336 | Search CTLA+4 | Search CTLA+4 |
9 | TIM 3 | 291388 | 1% | 81% | 131 | Search TIM+3 | Search TIM+3 |
10 | PEMBROLIZUMAB | 250413 | 1% | 78% | 118 | Search PEMBROLIZUMAB | Search PEMBROLIZUMAB |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PARDOLL, DM , (2012) THE BLOCKADE OF IMMUNE CHECKPOINTS IN CANCER IMMUNOTHERAPY.NATURE REVIEWS CANCER. VOL. 12. ISSUE 4. P. 252 -264 | 95 | 80% | 1583 |
2 | JOSEFOWICZ, SZ , LU, LF , RUDENSKY, AY , (2012) REGULATORY T CELLS: MECHANISMS OF DIFFERENTIATION AND FUNCTION.ANNUAL REVIEW OF IMMUNOLOGY, VOL 30. VOL. 30. ISSUE . P. 531 -564 | 156 | 69% | 697 |
3 | TOPALIAN, SL , DRAKE, CG , PARDOLL, DM , (2015) IMMUNE CHECKPOINT BLOCKADE: A COMMON DENOMINATOR APPROACH TO CANCER THERAPY.CANCER CELL. VOL. 27. ISSUE 4. P. 450 -461 | 94 | 88% | 250 |
4 | FRANCISCO, LM , SAGE, PT , SHARPE, AH , (2010) THE PD-1 PATHWAY IN TOLERANCE AND AUTOIMMUNITY.IMMUNOLOGICAL REVIEWS. VOL. 236. ISSUE . P. 219-242 | 165 | 81% | 414 |
5 | KEIR, ME , BUTTE, MJ , FREEMAN, GJ , SHARPEL, AH , (2008) PD-1 AND ITS LIGANDS IN TOLERANCE AND IMMUNITY.ANNUAL REVIEW OF IMMUNOLOGY. VOL. 26. ISSUE . P. 677 -704 | 119 | 80% | 1242 |
6 | POSTOW, MA , CALLAHAN, MK , WOLCHOK, JD , (2015) IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY.JOURNAL OF CLINICAL ONCOLOGY. VOL. 33. ISSUE 17. P. 1974 -U161 | 73 | 89% | 225 |
7 | GREENWALD, RJ , FREEMAN, GJ , SHARPE, AH , (2005) THE B7 FAMILY REVISITED.ANNUAL REVIEW OF IMMUNOLOGY. VOL. 23. ISSUE . P. 515 -548 | 129 | 87% | 1237 |
8 | BOUR-JORDAN, H , ESENSTEN, JH , MARTINEZ-LLORDELLA, M , PENARANDA, C , STUMPF, M , BLUESTONE, JA , (2011) INTRINSIC AND EXTRINSIC CONTROL OF PERIPHERAL T-CELL TOLERANCE BY COSTIMULATORY MOLECULES OF THE CD28/B7 FAMILY.IMMUNOLOGICAL REVIEWS. VOL. 241. ISSUE . P. 180 -205 | 195 | 73% | 154 |
9 | INTLEKOFER, AM , THOMPSON, CB , (2013) AT THE BENCH: PRECLINICAL RATIONALE FOR CTLA-4 AND PD-1 BLOCKADE AS CANCER IMMUNOTHERAPY.JOURNAL OF LEUKOCYTE BIOLOGY. VOL. 94. ISSUE 1. P. 25-39 | 155 | 90% | 63 |
10 | NGUYEN, LT , OHASHI, PS , (2015) CLINICAL BLOCKADE OF PD1 AND LAG3-POTENTIAL MECHANISMS OF ACTION.NATURE REVIEWS IMMUNOLOGY. VOL. 15. ISSUE 1. P. 45 -56 | 104 | 85% | 72 |
Classes with closest relation at Level 2 |